Browse drugs

…intensification or change was 1.6 (0.7) and 1.4 (0.7) years for semaglutide and alternative treatment, with no subgroup differences noted (…

…s associated with 11.9% greater weight reduction (13 RCTs), and tirzepatide was associated with 16.2% greater weight reduction (6 RCTs).51 …

…de (25 936), empagliflozin (715 802), sitagliptin (493 563) and glipizide (832 295) ( online supplemental eTable 1, 5–8). Baseline charac…

…, whereby researchers are investigating the use of subcutaneous semaglutide 2.4 mg/week for the treatment of adults with non-cirrhotic MASH…

…he results of the ongoing SEPRA trial, we found that injectable semaglutide was superior to SoC with 30% more patients achieving A1C <7% at…

…native treatments. Some PROs indicated greater improvement with semaglutide versus alternative treatment. No new safety concerns were ident…

…t met all response criteria (ELF, LSM-VCTE, histology) was 16% (semaglutide) vs 5.6% (pla-cebo).The incidence of serious adverse events in …

…atide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The as…

… among the GLP-1RA group compared with the sulfonylureas group. GLP-1RA=glucagon-like peptide-1 receptor agonistsDiscussionIn this nati…

…nsporter 2 inhibitors, and insulin, as well as length of use of metformin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 inhi…

…emic control (A1C <7%) than those initiating SoC. Additionally, semaglutide initiators had a 1.3% reduction in A1C, compared with a 1.1% re…

…pairs), 30-day mortality was 0% vs. 11.1% (p<0.001).Conclusions Semaglutide use was associated with lower mortality following AIS in a larg…